Sentences with phrase «future of oncology»
Most likely, the future of oncology will not rest on a single therapy but a precise combination of targeted drugs.
https://www.scientificamerican.com/ Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof - of - concept, plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.
If Novartis can get clinical trial success to translate into commercial success, it would bode extremely well for Gilead's future as a leader of this exciting new oncology space.
«This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer,» stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.
«Future comparative oncology studies, optimizing the delivery of PMed strategies, may aid cancer drug development.»
«Overall the turnaround for sample analyses fit a relevant clinical window for future comparative oncology trials to model human PMed advancements,» said Dr. William Hendricks, a TGen Staff Scientist and another author of the study.
«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.
Future studies are planned by Chang and other School of Medicine researchers — including senior author Kenneth R. Carson, MD, PhD, an assistant professor of oncology, and Graham Colditz, MD, DrPH, a cancer expert who also is associate director of prevention and control at Siteman Cancer Center at Washington University School of Medicine and Barnes - Jewish Hospital.
Tryfonidis et al. discuss perspectives and future directions for the management of locally advanced breast cancer in Nature Reviews Clinical Oncology, and they see a need for not only standardizing treatment for this disease, but also for developing new therapies that could substantially improve outcome.
«Identification of these variations has helped the family to better understand why their children developed cancer and to plan for the future,» said co-author Kim Nichols, M.D., a member of the St. Jude Oncology department and director of the St. Jude Cancer Predisposition Division.
«We urgently need markers to predict which therapies are going to be effective and which will not be effective in individual patients with advanced prostate cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.»
As one of the finest pediatric hematology - oncology fellowship programs in the nation, our centers are training fellows to obtain outstanding clinical and laboratory research knowledge, paving the future of pediatric cancer and blood disorder care.
His team will drive the discovery and development of compounds to support Moderna's existing and future research partnerships, as well as its internal efforts in rare diseases and oncology.
Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?
NJTV - New Pancreatic Study May Offer Hope for the Future - November 17, 2011 CINJ Deputy Director Dr. Edmund Lattime and Co-Director of CINJ's Gastrointestinal - Hepatobiliary Oncology Program Dr. Elizabeth Poplin discuss early results to a unique clinical trial that uses vaccine therapy to target pancreatic cancer.
The theme of this year's meeting is «Expanding horizons in Neurosciences: New approaches to Brain Activation», which will provide an international platform for discussion and sharing of novel ideas for present and future expansions in various fields of neurology such as Neuroimmunology, Neurological disorders, Neuro Oncology, Neuroimaging, Cognitive neuroscience and expertise meeting.
Archives of Dermatological Research, March 2010, pages 71 - 83; Skin Pharmacology and Physiology, September 2009, pages 299 - 304; Skin Research and Technology, August 2009, pages 338 - 345; Dermatologic Surgery, July 2009, pages 1,057 - 1,065; Experimental Dermatology, June 2009, pages 522 - 526; Clinics in Dermatology, November - December 2008, pages 614 - 626; Skin Therapy Letter, September 2008, pages 5 - 9; Journal of Drugs in Dermatology, July 2008, pages S7 - S12; Food and Chemical Toxicology, April 2008, pages 1,298 - 1,307; Journal of Toxicology and Environmental Health, Volume 72, pages 796 - 806; Future Oncology, December 2008, pages 841 - 856; Journal of Pathology, January 2007, 241 - 251; Journal of Radiation Research, December 2004, pages 491 - 495; British Journal of Dermatology, October 2003, page 681; and Journal of Dermatological Science, volume 31, 2003, pages 193 - 201; and Journal of Investigative Dermatology, November 2003, pages 1,163 - 1,167; and January 2002, pages 117 - 125.
The PCOP is integrally involved in educating and training the veterinary oncology team of the future.
He is currently working to develop the WCVM's human and technological resources in the areas of veterinary oncology and food safety and security — two areas that the college is focusing on for the future.
If you're interested in being one of these minds, working towards future advances in oncology, talk to us at Hays.